Author(s): YIU Zz, EXTON Ls, JABBAR Lopezz, MOHDMUSTAPA Mf, SAMARASEKERA Ej, BURDEN Ad, MURPHY R, OWEN Cm, PARSLEW R, VENNING V, ASHCROFT Dm, GRIFFITHS Ce, SMITH Ch, WARREN Rb, XUE Rujun
Pages: 224
Year: 2017 Issue:  3
Journal: Southern China Journal of Dermato-Venereology
Abstract: 肿瘤坏死因子抑制剂英夫利昔单抗、依那西普和阿达木单抗是目前用于治疗银屑病常用的3种生物制剂,新药优特克单抗是IL-12和IL-23拮抗剂,苏金单抗是IL-17受体拮抗剂.生物制剂通过抑制细胞因子,调控银屑病患者紊乱的免疫系统,从而发挥疗效.